首页 > 最新文献

PCN reports : psychiatry and clinical neurosciences最新文献

英文 中文
The web-based self-reported survey of Alcohol Use Disorders Identification Test and associated factors in Japan. 日本酒精使用障碍鉴定测试及相关因素的网上自我报告调查。
Pub Date : 2024-12-22 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70044
Tomomi Toyama, Chie Nitta, Yoshiki Koga, Kaoru Hamanaka, Mitsuru Kimura, Sachio Matsushita

Aim: While considerable data on the alcohol drinking behavior of the general population are available for the United States and Europe, data from Asian countries are scarce. We attempted to estimate the social backgrounds and other factors associated with high Alcohol Use Disorders Identification Test (AUDIT) scores in Japan.

Methods: This web-based survey was conducted in 2023. In order to ensure the representativeness of the sample, the population distribution by age and region was determined from the Statistics Bureau Census Basic Population Summary. The survey questionnaire items included AUDIT, educational background, occupation, income, marital status, body mass index (BMI), age at the time of the first alcoholic drink, age at the start of habitual drinking, Kessler Psychological Distress Scale (K6), and Link's Devaluation Discrimination Scale.

Results: A total of 40,720 responses were received from people aged between 20 and 75 years old. The proportion of potential alcohol use disorder based on AUDIT score ≥15 was 9.2% in men and 2.0% in women. The number of people with AUDIT scores ≥15 tended to be high in men in their 50s and women in their 20s and 40s. Among those with AUDIT scores ≥15, the age at the first drink and age at the start of habitual drinking were significantly lower, and the K6 score was significantly higher.

Conclusion: This web survey showed an association between AUDIT scores and age at first drinking and mental health condition. Since this survey was a web-monitored survey, caution should be taken in generalizing the prevalence.

目的:虽然美国和欧洲有大量关于普通人群饮酒行为的数据,但亚洲国家的数据很少。我们试图估计与日本高酒精使用障碍鉴定测试(AUDIT)分数相关的社会背景和其他因素。方法:该网络调查于2023年进行。为了保证样本的代表性,按年龄和地区划分的人口分布由统计局人口普查基本人口摘要确定。调查问卷项目包括:审计、学历、职业、收入、婚姻状况、体重指数(BMI)、首次饮酒年龄、开始习惯饮酒年龄、Kessler心理困扰量表(K6)、Link贬值歧视量表。结果:共收到40,720份来自20至75岁人群的回复。基于AUDIT评分≥15的潜在酒精使用障碍比例在男性中为9.2%,在女性中为2.0%。审计得分≥15分的人数在50多岁的男性和20多岁和40多岁的女性中往往较多。在AUDIT评分≥15分的人群中,首次饮酒年龄和开始习惯性饮酒年龄显著低于对照组,K6评分显著高于对照组。结论:本网络调查显示初饮年龄和心理健康状况与审计得分有一定的相关性。由于这项调查是一项网络监测调查,因此在概括患病率时应谨慎。
{"title":"The web-based self-reported survey of Alcohol Use Disorders Identification Test and associated factors in Japan.","authors":"Tomomi Toyama, Chie Nitta, Yoshiki Koga, Kaoru Hamanaka, Mitsuru Kimura, Sachio Matsushita","doi":"10.1002/pcn5.70044","DOIUrl":"10.1002/pcn5.70044","url":null,"abstract":"<p><strong>Aim: </strong>While considerable data on the alcohol drinking behavior of the general population are available for the United States and Europe, data from Asian countries are scarce. We attempted to estimate the social backgrounds and other factors associated with high Alcohol Use Disorders Identification Test (AUDIT) scores in Japan.</p><p><strong>Methods: </strong>This web-based survey was conducted in 2023. In order to ensure the representativeness of the sample, the population distribution by age and region was determined from the Statistics Bureau Census Basic Population Summary. The survey questionnaire items included AUDIT, educational background, occupation, income, marital status, body mass index (BMI), age at the time of the first alcoholic drink, age at the start of habitual drinking, Kessler Psychological Distress Scale (K6), and Link's Devaluation Discrimination Scale.</p><p><strong>Results: </strong>A total of 40,720 responses were received from people aged between 20 and 75 years old. The proportion of potential alcohol use disorder based on AUDIT score ≥15 was 9.2% in men and 2.0% in women. The number of people with AUDIT scores ≥15 tended to be high in men in their 50s and women in their 20s and 40s. Among those with AUDIT scores ≥15, the age at the first drink and age at the start of habitual drinking were significantly lower, and the K6 score was significantly higher.</p><p><strong>Conclusion: </strong>This web survey showed an association between AUDIT scores and age at first drinking and mental health condition. Since this survey was a web-monitored survey, caution should be taken in generalizing the prevalence.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70044"},"PeriodicalIF":0.0,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11663248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of the Japanese version of the Public Attitudes Toward Epilepsy (PATE-J) Scale. 日本版公众对癫痫的态度(PATE-J)量表的开发和验证。
Pub Date : 2024-12-20 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70045
Junichi Hatakeda, Hiroumi Shimazaki, Izumi Kuramochi, Takayuki Iwayama, Sayaka Kobayashi, Hideyuki Matsuki, Haruo Yoshimasu, Kheng Seang Lim

Aim: This study aimed to develop and validate a Japanese version of the Public Attitudes Toward Epilepsy (PATE-J) Scale to measure attitudes towards epilepsy among the general Japanese population.

Methods: The study employed a cross-sectional design using an online survey of 537 participants from the general public in Japan, with follow-up surveys at 2 weeks and 3 months. The PATE Scale was translated following standard guidelines and validated by conducting confirmatory factor analysis (CFA) on the complete data set to assess the original two-factor structure of the PATE Scale. Internal consistency assessment, and convergent validity testing with the Modified Epilepsy Stigma Scale (M-ESS), Perceived Devaluation Discrimination Scale (PDDS), and Epilepsy Knowledge Scale (EKS) were carried out.

Results: CFA confirmed the two-factor structure of the PATE-J, comprising "Personal Domain" and "General Domain." The model showed acceptable fit indices (χ²(76) = 607.974, comparative fit index = 0.849, Tucker-Lewis index = 0.820, root-mean-square error of approximation = 0.114, standardized root-mean-square residual = 0.078) and high reliability (Cronbach's α = 0.87 for Personal Domain and 0.75 for General Domain). Strong correlations with the M-ESS (r = 0.713, p < 0.001), and weaker correlations with the PDDS, along with a negative correlation with the EKS (r = -0.306, p < 0.001), highlighted the PATE-J's distinctiveness. No significant associations were found between demographic factors and PATE-J scores.

Conclusion: The PATE-J demonstrates strong psychometric properties and cultural relevance for measuring public attitudes toward epilepsy in Japan. Its validated two-factor structure supports cross-cultural comparisons and provides a reliable tool for assessing public attitudes, informing interventions, and guiding education campaigns.

目的:本研究旨在开发和验证日本版本的公众对癫痫的态度(PATE-J)量表,以衡量日本普通人群对癫痫的态度。方法:本研究采用横断面设计,对537名日本普通民众进行在线调查,随访时间分别为2周和3个月。PATE量表按照标准指南进行翻译,并通过对完整数据集进行验证性因子分析(CFA)进行验证,以评估PATE量表的原始双因素结构。采用改良癫痫病耻感量表(M-ESS)、感知贬值歧视量表(PDDS)和癫痫知识量表(EKS)进行内部一致性评估和收敛效度检验。结果:CFA证实了PATE-J的双因子结构,包括“个人域”和“一般域”。模型具有良好的拟合指数(χ²(76)= 607.974,比较拟合指数= 0.849,Tucker-Lewis指数= 0.820,近似均方根误差= 0.114,标准化均方根残差= 0.078)和高信度(个人域的Cronbach′s α = 0.87,一般域的Cronbach′s α = 0.75)。结论:在测量日本公众对癫痫的态度时,PATE-J具有很强的心理测量特性和文化相关性。其经过验证的双因素结构支持跨文化比较,并为评估公众态度、告知干预措施和指导教育活动提供可靠的工具。
{"title":"Development and validation of the Japanese version of the Public Attitudes Toward Epilepsy (PATE-J) Scale.","authors":"Junichi Hatakeda, Hiroumi Shimazaki, Izumi Kuramochi, Takayuki Iwayama, Sayaka Kobayashi, Hideyuki Matsuki, Haruo Yoshimasu, Kheng Seang Lim","doi":"10.1002/pcn5.70045","DOIUrl":"10.1002/pcn5.70045","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to develop and validate a Japanese version of the Public Attitudes Toward Epilepsy (PATE-J) Scale to measure attitudes towards epilepsy among the general Japanese population.</p><p><strong>Methods: </strong>The study employed a cross-sectional design using an online survey of 537 participants from the general public in Japan, with follow-up surveys at 2 weeks and 3 months. The PATE Scale was translated following standard guidelines and validated by conducting confirmatory factor analysis (CFA) on the complete data set to assess the original two-factor structure of the PATE Scale. Internal consistency assessment, and convergent validity testing with the Modified Epilepsy Stigma Scale (M-ESS), Perceived Devaluation Discrimination Scale (PDDS), and Epilepsy Knowledge Scale (EKS) were carried out.</p><p><strong>Results: </strong>CFA confirmed the two-factor structure of the PATE-J, comprising \"Personal Domain\" and \"General Domain.\" The model showed acceptable fit indices (<i>χ</i>²(76) = 607.974, comparative fit index = 0.849, Tucker-Lewis index = 0.820, root-mean-square error of approximation = 0.114, standardized root-mean-square residual = 0.078) and high reliability (Cronbach's <i>α</i> = 0.87 for Personal Domain and 0.75 for General Domain). Strong correlations with the M-ESS (<i>r</i> = 0.713, <i>p</i> < 0.001), and weaker correlations with the PDDS, along with a negative correlation with the EKS (<i>r</i> = -0.306, <i>p</i> < 0.001), highlighted the PATE-J's distinctiveness. No significant associations were found between demographic factors and PATE-J scores.</p><p><strong>Conclusion: </strong>The PATE-J demonstrates strong psychometric properties and cultural relevance for measuring public attitudes toward epilepsy in Japan. Its validated two-factor structure supports cross-cultural comparisons and provides a reliable tool for assessing public attitudes, informing interventions, and guiding education campaigns.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70045"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The COVID-19 pandemic-induced behavioral restrictions and their impact on child and adolescent psychiatric units-Infection control or freedom. COVID-19大流行引发的行为限制及其对儿童和青少年精神病院的影响——感染控制或自由
Pub Date : 2024-12-17 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70047
Masahide Usami, Yoshinori Sasaki, Mayuna Ichikawa, Miki Matsudo, Mutsumi Ohashi, Yui Higashino, Yusuke Kono, Haruna Matsudo, Yuki Nomura, Minjae Ma, Yuuki Sakoh, Maiko Odaka, Kotoe Itagaki, Keita Yamamoto, Momoka Takahashi, Yuta Yoshimura, Saori Inoue, Masahiro Ishida, Kumi Inazaki, Yuki Hakoshima, Yuki Mizumoto

Aim: This study examines the impact of COVID-19 pandemic-induced behavioral restrictions on child psychiatric inpatients in Japan, particularly focusing on limitations placed on outings and overnight stays as infection-control measures.

Methods: Data were collected from inpatients from the children's mental health registry between January 2016 and December 2022. The clinical data, such as age, gender, diagnosis, result of polymerase chain reaction (PCR) tests, frequency of outings and overnight stays before and after the pandemic, were compared.

Results: During the COVID-19 pandemic, the decrease in both outings and overnight stays among child psychiatric inpatients in Japan was statistically significant. As a result, home interactions with families decreased. In addition, diagnoses of hospitalized children increased significantly in cases of eating disorders and decreased in diagnoses of autism spectrum disorders.

Conclusion: These results underscore the need for flexible, individualized approaches to infection control that consider the mental health of hospitalized children.

目的:本研究探讨了COVID-19大流行引发的行为限制对日本儿童精神科住院患者的影响,特别关注了作为感染控制措施的外出和过夜限制。方法:收集2016年1月至2022年12月儿童心理健康登记处住院患者的数据。比较大流行前后年龄、性别、诊断、聚合酶链反应(PCR)检测结果、外出次数和过夜次数等临床数据。结果:新冠肺炎大流行期间,日本儿童精神科住院患者外出和过夜次数均有统计学意义。结果,家庭间的互动减少了。此外,住院儿童的饮食失调诊断率显著增加,自闭症谱系障碍诊断率显著下降。结论:这些结果强调需要灵活、个性化的方法来控制感染,同时考虑住院儿童的心理健康。
{"title":"The COVID-19 pandemic-induced behavioral restrictions and their impact on child and adolescent psychiatric units-Infection control or freedom.","authors":"Masahide Usami, Yoshinori Sasaki, Mayuna Ichikawa, Miki Matsudo, Mutsumi Ohashi, Yui Higashino, Yusuke Kono, Haruna Matsudo, Yuki Nomura, Minjae Ma, Yuuki Sakoh, Maiko Odaka, Kotoe Itagaki, Keita Yamamoto, Momoka Takahashi, Yuta Yoshimura, Saori Inoue, Masahiro Ishida, Kumi Inazaki, Yuki Hakoshima, Yuki Mizumoto","doi":"10.1002/pcn5.70047","DOIUrl":"10.1002/pcn5.70047","url":null,"abstract":"<p><strong>Aim: </strong>This study examines the impact of COVID-19 pandemic-induced behavioral restrictions on child psychiatric inpatients in Japan, particularly focusing on limitations placed on outings and overnight stays as infection-control measures.</p><p><strong>Methods: </strong>Data were collected from inpatients from the children's mental health registry between January 2016 and December 2022. The clinical data, such as age, gender, diagnosis, result of polymerase chain reaction (PCR) tests, frequency of outings and overnight stays before and after the pandemic, were compared.</p><p><strong>Results: </strong>During the COVID-19 pandemic, the decrease in both outings and overnight stays among child psychiatric inpatients in Japan was statistically significant. As a result, home interactions with families decreased. In addition, diagnoses of hospitalized children increased significantly in cases of eating disorders and decreased in diagnoses of autism spectrum disorders.</p><p><strong>Conclusion: </strong>These results underscore the need for flexible, individualized approaches to infection control that consider the mental health of hospitalized children.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70047"},"PeriodicalIF":0.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652781/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunization-related complex regional pain syndrome: A systematic review of case reports. 免疫相关的复杂区域性疼痛综合征:病例报告的系统回顾。
Pub Date : 2024-12-10 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70041
William K Copenhaver, Brandon J Goodwin, Alexa Simonetti, Kunal P Shah, Nicholas J Averell, David F Lo, Richard T Jermyn

Aim: Vaccines have been shown to have the highest efficacy in preventing infectious diseases through their ability to induce immunological memory against pathogens. An adverse reaction to a vaccine is an unexpected medical occurrence following immunization. Complex regional pain syndrome (CRPS) is a disease that has undergone much controversy regarding its onset post-vaccination. This systematic review aims to evaluate cases of CRPS post-vaccination to better understand the manifestation of the disease and its potential association with vaccines.

Methods: A systematic review of case reports was conducted employing the PRISMA 2020 guidelines. Outcomes of interest include type of vaccination, patient age, patient sex, time to symptom onset, and medical history including but not limited to previous autoimmune diseases, psychological illness, physical tissue trauma, and neurological disease.

Results: Initial querying of the five databases yielded 404 articles. Following a thorough review of articles, only 14 remained, comprising 18 cases. Studies included cases of CRPS development following tetanus, hepatitis B, hepatitis A, rubella, influenza, tetanus-diphtheria, human papillomavirus, and COVID-19 vaccine administration.

Conclusion: The limitations of evidence used in this study highlight the need for a greater output of higher-level evidence in the form of controlled trials and retrospective studies to help further elucidate the connection between vaccine use and the development of CRPS in patients. Currently, vaccines continue to be safe for global public use.

目的:疫苗通过诱导对病原体的免疫记忆能力,已被证明在预防传染病方面具有最高功效。疫苗不良反应是免疫接种后意外发生的医学事件。复杂区域疼痛综合征(CRPS)是一种疾病,已经历了许多争议,其发病后疫苗接种。本系统综述旨在评估疫苗接种后CRPS病例,以更好地了解该病的表现及其与疫苗的潜在关联。方法:采用PRISMA 2020指南对病例报告进行系统回顾。结果包括疫苗接种类型、患者年龄、患者性别、症状发作时间和病史,包括但不限于既往自身免疫性疾病、心理疾病、身体组织创伤和神经系统疾病。结果:对5个数据库进行初步查询,得到404篇文章。在彻底审查条款后,只剩下14条,包括18个案件。研究包括破伤风、乙型肝炎、甲型肝炎、风疹、流感、破伤风-白喉、人乳头瘤病毒和COVID-19疫苗接种后发生CRPS的病例。结论:本研究中使用的证据的局限性突出表明,需要以对照试验和回顾性研究的形式提供更多更高水平的证据,以帮助进一步阐明疫苗使用与患者CRPS发生之间的联系。目前,疫苗对全球公众使用仍然是安全的。
{"title":"Immunization-related complex regional pain syndrome: A systematic review of case reports.","authors":"William K Copenhaver, Brandon J Goodwin, Alexa Simonetti, Kunal P Shah, Nicholas J Averell, David F Lo, Richard T Jermyn","doi":"10.1002/pcn5.70041","DOIUrl":"10.1002/pcn5.70041","url":null,"abstract":"<p><strong>Aim: </strong>Vaccines have been shown to have the highest efficacy in preventing infectious diseases through their ability to induce immunological memory against pathogens. An adverse reaction to a vaccine is an unexpected medical occurrence following immunization. Complex regional pain syndrome (CRPS) is a disease that has undergone much controversy regarding its onset post-vaccination. This systematic review aims to evaluate cases of CRPS post-vaccination to better understand the manifestation of the disease and its potential association with vaccines.</p><p><strong>Methods: </strong>A systematic review of case reports was conducted employing the PRISMA 2020 guidelines. Outcomes of interest include type of vaccination, patient age, patient sex, time to symptom onset, and medical history including but not limited to previous autoimmune diseases, psychological illness, physical tissue trauma, and neurological disease.</p><p><strong>Results: </strong>Initial querying of the five databases yielded 404 articles. Following a thorough review of articles, only 14 remained, comprising 18 cases. Studies included cases of CRPS development following tetanus, hepatitis B, hepatitis A, rubella, influenza, tetanus-diphtheria, human papillomavirus, and COVID-19 vaccine administration.</p><p><strong>Conclusion: </strong>The limitations of evidence used in this study highlight the need for a greater output of higher-level evidence in the form of controlled trials and retrospective studies to help further elucidate the connection between vaccine use and the development of CRPS in patients. Currently, vaccines continue to be safe for global public use.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70041"},"PeriodicalIF":0.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11631839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impacts of hospital admission in very late-onset schizophrenia-like psychosis: A case report. 住院治疗对迟发性精神分裂症样精神病的影响:1例报告。
Pub Date : 2024-12-10 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70040
Shigeki Katakami, Yuto Satake, Takashi Suehiro, Daiki Ishimaru, Erina Nakanishi, Hideki Kanemoto, Kenji Yoshiyama, Manabu Ikeda

Background: Very late-onset schizophrenia-like psychosis (VLOSLP) is a psychotic disorder with an age of onset ≥60 years, and social isolation is a risk factor. Reports on the impact of interventions for isolation and loneliness on psychiatric symptoms in VLOSLP are limited.

Case presentation: An 87-year-old woman, widowed and living alone, developed psychosis, including paranoia, erotomania, and visual hallucinations, at 84 years old during a period when her interactions with others were limited by the COVID-19 pandemic and osteoarthritis. She was eventually brought to our hospital with a local dementia outreach team. She was admitted and diagnosed with VLOSLP with mild cognitive decline through imaging and neuropsychological tests confirming the absence of dementia. Immediately after admission, her psychotic symptoms became inactive. She was transferred to another psychiatric hospital to prepare for her move to a long-term care facility because her psychosis was alleviated. During admission, she enjoyed the company of others and occupational therapy, and her score on the UCLA Loneliness Scale Version 3 improved from 44 at admission to 35 at discharge.

Conclusion: The admission itself improved the patient's psychosis, which seemed to be related to the alleviation of isolation and loneliness.

背景:极晚发性精神分裂症样精神病(VLOSLP)是一种发病年龄≥60岁的精神障碍,社会孤立是其危险因素。关于隔离和孤独干预措施对VLOSLP精神症状影响的报道有限。病例介绍:一名87岁独居寡妇,84岁时因COVID-19大流行和骨关节炎与他人的互动受到限制,出现精神病,包括偏执、情欲狂和视觉幻觉。她最终被当地的痴呆症救助小组送到了我们的医院。她入院并被诊断为VLOSLP,通过影像学和神经心理学测试证实没有痴呆,伴有轻度认知能力下降。入院后,她的精神病症状立即消失。她被转移到另一家精神病院,准备转入长期护理机构,因为她的精神病得到缓解。在入院期间,她喜欢他人的陪伴和职业治疗,她在加州大学洛杉矶分校孤独量表第三版中的得分从入院时的44分提高到出院时的35分。结论:住院本身改善了患者的精神状态,这可能与隔离和孤独感的减轻有关。
{"title":"The impacts of hospital admission in very late-onset schizophrenia-like psychosis: A case report.","authors":"Shigeki Katakami, Yuto Satake, Takashi Suehiro, Daiki Ishimaru, Erina Nakanishi, Hideki Kanemoto, Kenji Yoshiyama, Manabu Ikeda","doi":"10.1002/pcn5.70040","DOIUrl":"10.1002/pcn5.70040","url":null,"abstract":"<p><strong>Background: </strong>Very late-onset schizophrenia-like psychosis (VLOSLP) is a psychotic disorder with an age of onset ≥60 years, and social isolation is a risk factor. Reports on the impact of interventions for isolation and loneliness on psychiatric symptoms in VLOSLP are limited.</p><p><strong>Case presentation: </strong>An 87-year-old woman, widowed and living alone, developed psychosis, including paranoia, erotomania, and visual hallucinations, at 84 years old during a period when her interactions with others were limited by the COVID-19 pandemic and osteoarthritis. She was eventually brought to our hospital with a local dementia outreach team. She was admitted and diagnosed with VLOSLP with mild cognitive decline through imaging and neuropsychological tests confirming the absence of dementia. Immediately after admission, her psychotic symptoms became inactive. She was transferred to another psychiatric hospital to prepare for her move to a long-term care facility because her psychosis was alleviated. During admission, she enjoyed the company of others and occupational therapy, and her score on the UCLA Loneliness Scale Version 3 improved from 44 at admission to 35 at discharge.</p><p><strong>Conclusion: </strong>The admission itself improved the patient's psychosis, which seemed to be related to the alleviation of isolation and loneliness.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70040"},"PeriodicalIF":0.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11632116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142815173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia. 鲁拉西酮在精神分裂症孕妇体内药代动力学的变化。
Pub Date : 2024-12-09 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70043
Mihoko Kawai, Ryosuke Aratake, Tadashi Ogawa

Background: The population of pregnant women with schizophrenia is increasing. Managing schizophrenia during pregnancy poses unique challenges due to the potential effects of second-generation antipsychotics on maternal mental health and fetal development and changes in drug pharmacokinetics. Evidence on how physiological changes during pregnancy affect the levels of second-generation antipsychotics, particularly lurasidone, is limited. There are no data on effectively managing medications and decreasing side-effects during pregnancy.

Case presentation: We presented the case of a 34-year-old pregnant woman with schizophrenia who had a stable condition with lurasidone therapy before conception. However, she exhibited worsening psychiatric symptoms during the third trimester of pregnancy. Serial measurements of serum lurasidone levels were performed during late pregnancy. Despite maintaining the same dosage, her serum lurasidone levels significantly decreased during the third trimester (maximum decrease of ~65% compared with baseline) and rapidly increased during the postpartum period, coinciding with an improvement in psychiatric symptoms.

Conclusion: Decreased serum lurasidone levels during pregnancy may increase the risk of symptom worsening in patients with schizophrenia. Hence, clinicians should be knowledgeable about the risk of decreased drug levels and the need for therapeutic monitoring and dosage adjustments during pregnancy to maintain treatment efficacy and maternal and fetal health.

背景:孕妇患精神分裂症的人数正在增加。由于第二代抗精神病药物对孕产妇心理健康和胎儿发育的潜在影响以及药物药代动力学的变化,妊娠期精神分裂症的管理面临着独特的挑战。关于怀孕期间生理变化如何影响第二代抗精神病药物,特别是鲁拉西酮水平的证据是有限的。没有关于有效管理药物和减少怀孕期间副作用的数据。病例介绍:我们报告了一例34岁的精神分裂症孕妇,她在怀孕前接受鲁拉西酮治疗病情稳定。然而,她在妊娠晚期表现出恶化的精神症状。在妊娠后期进行血清鲁拉西酮水平的连续测量。尽管维持相同的剂量,她的血清鲁拉西酮水平在妊娠晚期显著下降(与基线相比最大下降约65%),并在产后迅速上升,与精神症状的改善相一致。结论:妊娠期血清鲁拉西酮水平降低可能增加精神分裂症患者症状恶化的风险。因此,临床医生应该了解药物水平降低的风险,以及在怀孕期间进行治疗监测和剂量调整的必要性,以保持治疗效果和母婴健康。
{"title":"Changes in the pharmacokinetics of lurasidone in a pregnant woman with schizophrenia.","authors":"Mihoko Kawai, Ryosuke Aratake, Tadashi Ogawa","doi":"10.1002/pcn5.70043","DOIUrl":"10.1002/pcn5.70043","url":null,"abstract":"<p><strong>Background: </strong>The population of pregnant women with schizophrenia is increasing. Managing schizophrenia during pregnancy poses unique challenges due to the potential effects of second-generation antipsychotics on maternal mental health and fetal development and changes in drug pharmacokinetics. Evidence on how physiological changes during pregnancy affect the levels of second-generation antipsychotics, particularly lurasidone, is limited. There are no data on effectively managing medications and decreasing side-effects during pregnancy.</p><p><strong>Case presentation: </strong>We presented the case of a 34-year-old pregnant woman with schizophrenia who had a stable condition with lurasidone therapy before conception. However, she exhibited worsening psychiatric symptoms during the third trimester of pregnancy. Serial measurements of serum lurasidone levels were performed during late pregnancy. Despite maintaining the same dosage, her serum lurasidone levels significantly decreased during the third trimester (maximum decrease of ~65% compared with baseline) and rapidly increased during the postpartum period, coinciding with an improvement in psychiatric symptoms.</p><p><strong>Conclusion: </strong>Decreased serum lurasidone levels during pregnancy may increase the risk of symptom worsening in patients with schizophrenia. Hence, clinicians should be knowledgeable about the risk of decreased drug levels and the need for therapeutic monitoring and dosage adjustments during pregnancy to maintain treatment efficacy and maternal and fetal health.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70043"},"PeriodicalIF":0.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11628732/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142808541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of patients with neurotic disorders requiring long-term treatment: Relationship to "nervous personality" as described in Morita's Shinkeishitsu theory. 需要长期治疗的神经性疾病患者的特征:与森田新keishitsu理论中描述的“神经质人格”的关系。
Pub Date : 2024-12-05 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70039
Hiroshi Matsumoto, Takashi Uchino, Tomoyuki Funatogawa, Masafumi Mizuno, Takahiro Nemoto

Aim: Few studies have investigated the association between premorbid personality and the prognosis of neurotic disorders. The aim of this study was to investigate the relationship between the presence of a "nervous personality" described in Morita's Shinkeishitsu theory and the duration of treatment in patients with neurotic disorders.

Methods: The study included 70 patients aged ≥15 years old who first visited the Department of Psychiatry, Toho University Omori Medical Center, between January 2010 and December 2010 and were diagnosed as having neurotic disorders. The subjects' medical records over a 10-year period from 2010 until 2020 were examined retrospectively to determine the influence of the presence of a "nervous personality" in the subjects on the duration of their treatment.

Results: There were no significant differences in the basic demographic characteristics or severity of illness at the first visit between groups with and without a "nervous personality." The mean and median duration of treatment were 25 months and 5 months in the group with a "nervous personality," and 5 months and 2 months in the group without a "nervous personality," respectively. Kaplan-Meier analysis revealed a significant difference in the duration of treatment between the two groups. Multiple regression analysis performed using treatment duration as the dependent variable identified only presence of a "nervous personality" among the independent variables as a significant factor influencing the duration of treatment, with the duration of treatment being 20 months longer in the group of subjects with a "nervous personality."

Conclusion: The presence of a "nervous personality," as described in Morita's Shinkeishitsu theory, may prolong the required duration of treatment in patients with neurotic disorders.

目的:很少有研究探讨发病前人格与神经性疾病预后的关系。本研究的目的是调查森田新敬理论中描述的“神经质人格”的存在与神经性障碍患者治疗时间之间的关系。方法:本研究纳入2010年1月至2010年12月在东宝大学大森医学中心精神科首次就诊的70例年龄≥15岁并被诊断为神经性障碍的患者。从2010年到2020年的10年间,研究人员对受试者的医疗记录进行了回顾性检查,以确定受试者中“神经质人格”的存在对治疗持续时间的影响。结果:在有和没有“神经质人格”的两组患者首次就诊时,基本人口学特征和疾病严重程度没有显著差异。“神经质人格”组的平均治疗时间和中位治疗时间分别为25个月和5个月,非“神经质人格”组的平均治疗时间和中位治疗时间分别为5个月和2个月。Kaplan-Meier分析显示两组治疗时间有显著差异。使用治疗持续时间作为因变量进行的多元回归分析发现,在自变量中,只有“神经型人格”的存在是影响治疗持续时间的重要因素,“神经型人格”组的治疗持续时间比“神经型人格”组长20个月。结论:正如森田新keishitsu理论所描述的,“神经性人格”的存在可能会延长神经性疾病患者所需的治疗时间。
{"title":"Characteristics of patients with neurotic disorders requiring long-term treatment: Relationship to \"nervous personality\" as described in Morita's <i>Shinkeishitsu</i> theory.","authors":"Hiroshi Matsumoto, Takashi Uchino, Tomoyuki Funatogawa, Masafumi Mizuno, Takahiro Nemoto","doi":"10.1002/pcn5.70039","DOIUrl":"10.1002/pcn5.70039","url":null,"abstract":"<p><strong>Aim: </strong>Few studies have investigated the association between premorbid personality and the prognosis of neurotic disorders. The aim of this study was to investigate the relationship between the presence of a \"nervous personality\" described in Morita's <i>Shinkeishitsu</i> theory and the duration of treatment in patients with neurotic disorders.</p><p><strong>Methods: </strong>The study included 70 patients aged ≥15 years old who first visited the Department of Psychiatry, Toho University Omori Medical Center, between January 2010 and December 2010 and were diagnosed as having neurotic disorders. The subjects' medical records over a 10-year period from 2010 until 2020 were examined retrospectively to determine the influence of the presence of a \"nervous personality\" in the subjects on the duration of their treatment.</p><p><strong>Results: </strong>There were no significant differences in the basic demographic characteristics or severity of illness at the first visit between groups with and without a \"nervous personality.\" The mean and median duration of treatment were 25 months and 5 months in the group with a \"nervous personality,\" and 5 months and 2 months in the group without a \"nervous personality,\" respectively. Kaplan-Meier analysis revealed a significant difference in the duration of treatment between the two groups. Multiple regression analysis performed using treatment duration as the dependent variable identified only presence of a \"nervous personality\" among the independent variables as a significant factor influencing the duration of treatment, with the duration of treatment being 20 months longer in the group of subjects with a \"nervous personality.\"</p><p><strong>Conclusion: </strong>The presence of a \"nervous personality,\" as described in Morita's <i>Shinkeishitsu</i> theory, may prolong the required duration of treatment in patients with neurotic disorders.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70039"},"PeriodicalIF":0.0,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11618883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials. 静脉注射氯胺酮、裸盖菇素和θ波爆发刺激治疗重度抑郁症的抗抑郁效果和安全性比较:随机对照试验的系统综述和网络荟萃分析。
Pub Date : 2024-12-04 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70042
Itsuki Terao, Wakako Kodama

The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta-analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined. We systematically searched the CENTRAL, Medline, CINHAL, and ClinicalTrials.gov databases for randomized controlled trials up to July 4, 2024. Random-effects network meta-analyses were conducted to compare the Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorderantidepressant efficacy, tolerability, and acceptability of IV ketamine, psilocybin, and TBS. Twenty-eight RCTs were included. All treatments were superior to placebo, with IV ketamine and psilocybin showing significantly greater antidepressant efficacy than TBS. No significant differences were detected between all treatments and placebo in tolerability and acceptability. In a subgroup analysis focusing on short periods of 1 week or less, only IV ketamine was significantly more effective than placebo. In another subgroup analysis focusing on periods of 4 weeks or longer, IV ketamine and psilocybin showed significantly better antidepressant effects than placebo. The confidence in the evidence ranged from very low to moderate. Specifically, there is a scarcity of studies on psilocybin and a lack of direct comparison trials. The findings suggest that IV ketamine and psilocybin may be more effective treatments compared to TBS. Additionally, IV ketamine may have an advantage in terms of rapid onset of action. The number of included studies is limited, especially for psilocybin, and therefore the current findings are preliminary, necessitating further accumulation of direct-comparison RCTs.

通过随机对照试验(RCTs)的荟萃分析,静脉注射氯胺酮(IV)、裸盖菇素和θ波爆发刺激(TBS)治疗重度抑郁症的个体疗效和安全性已经得到证实,但这些新疗法的相对有效性尚未得到充分检验。我们系统地检索了截至2024年7月4日的CENTRAL、Medline、CINHAL和ClinicalTrials.gov数据库中的随机对照试验。采用随机效应网络meta分析,比较静脉注射氯胺酮、裸盖菇素和θ波爆发刺激治疗重度抑郁症的抗抑郁效果和安全性,以及静脉注射氯胺酮、裸盖菇素和TBS的抗抑郁疗效、耐受性和可接受性。纳入28项随机对照试验。所有治疗均优于安慰剂,静脉注射氯胺酮和裸盖菇素的抗抑郁疗效明显高于TBS。所有治疗与安慰剂在耐受性和可接受性方面均无显著差异。在针对短时间1周或更短时间的亚组分析中,只有IV氯胺酮明显比安慰剂更有效。在另一个关注4周或更长时间的亚组分析中,IV氯胺酮和裸盖菇素的抗抑郁效果明显优于安慰剂。证据的可信度从极低到中等不等。具体来说,关于裸盖菇素的研究很少,也缺乏直接的比较试验。研究结果表明,与TBS相比,静脉注射氯胺酮和裸盖菇素可能更有效。此外,静脉注射氯胺酮在快速起效方面可能具有优势。纳入的研究数量有限,特别是对裸盖菇素的研究,因此目前的研究结果是初步的,需要进一步积累直接比较rct。
{"title":"Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.","authors":"Itsuki Terao, Wakako Kodama","doi":"10.1002/pcn5.70042","DOIUrl":"10.1002/pcn5.70042","url":null,"abstract":"<p><p>The individual efficacy and safety of intravenous racemic (IV) ketamine, psilocybin, and theta burst stimulation (TBS) for major depressive disorder have been demonstrated through meta-analyses of randomized controlled trials (RCTs), but the comparative usefulness of these novel treatments has not yet been fully examined. We systematically searched the CENTRAL, Medline, CINHAL, and ClinicalTrials.gov databases for randomized controlled trials up to July 4, 2024. Random-effects network meta-analyses were conducted to compare the Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorderantidepressant efficacy, tolerability, and acceptability of IV ketamine, psilocybin, and TBS. Twenty-eight RCTs were included. All treatments were superior to placebo, with IV ketamine and psilocybin showing significantly greater antidepressant efficacy than TBS. No significant differences were detected between all treatments and placebo in tolerability and acceptability. In a subgroup analysis focusing on short periods of 1 week or less, only IV ketamine was significantly more effective than placebo. In another subgroup analysis focusing on periods of 4 weeks or longer, IV ketamine and psilocybin showed significantly better antidepressant effects than placebo. The confidence in the evidence ranged from very low to moderate. Specifically, there is a scarcity of studies on psilocybin and a lack of direct comparison trials. The findings suggest that IV ketamine and psilocybin may be more effective treatments compared to TBS. Additionally, IV ketamine may have an advantage in terms of rapid onset of action. The number of included studies is limited, especially for psilocybin, and therefore the current findings are preliminary, necessitating further accumulation of direct-comparison RCTs.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70042"},"PeriodicalIF":0.0,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11617594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142788053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of the drinking habits of people who overdose over-the-counter drugs: Insights from a nationwide Japanese survey. 过量服用非处方药的人的饮酒习惯特征:来自日本全国调查的见解。
Pub Date : 2024-12-02 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70027
Satomi Mizuno, Satoshi Inoura, Toshihiko Matsumoto, Takuya Shimane

Aim: To analyze the drinking habits of individuals who overdosed on over-the-counter (OTC) drugs, such as cough suppressants, antitussives, antipyretic analgesics, and combination cold medications, in Japan.

Methods: This cross-sectional study analyzed data collected from 2881 participants through a national survey conducted in Japan in 2023. Through a self-administered questionnaire, the participants were categorized into OTC (overdosed OTC drugs in the past year) and control (did not overdose OTC drugs) groups. Variables related to drinking habits, social background, smoking habits, use of other medications, such as analgesics, tranquilizers, controlled drugs, and products containing high concentrations of caffeine, and perception of OTC drugs were compared between the two groups. Additionally, we matched the participants in the OTC (n = 25) and control (n = 100) groups by sex and age in a 1:4 ratio to assess these variables. Multivariate analyses were performed to examine how these factors are associated with drinking habits in individuals with OTC drug overdose.

Results: OTC drug overdose was prevalent among teenagers and those in their 50s, and was associated with habitual binge drinking and consumption of energy drinks. Those overdosing on OTC drugs obtained them mostly from drugstores and pharmacies.

Conclusion: This is the first study to show a relationship between drinking habits and OTC drug overdose. An understanding of the characteristics of drinking habits in those who overdose on OTC drugs can help reduce fatal health risks in this population.

目的:分析日本过量使用非处方药物(OTC)(如止咳药、止咳药、解热镇痛药和复方感冒药)的个体的饮酒习惯。方法:这项横断面研究分析了2023年在日本进行的一项全国性调查中收集的2881名参与者的数据。通过一份自我填写的问卷,参与者被分为OTC组(过去一年服用过量的非处方药)和control组(未服用过量的非处方药)。与饮酒习惯、社会背景、吸烟习惯、使用其他药物(如镇痛剂、镇静剂、管制药物和含有高浓度咖啡因的产品)以及对非处方药的认知相关的变量在两组之间进行了比较。此外,我们将OTC组(n = 25)和对照组(n = 100)的参与者按性别和年龄按1:4的比例进行匹配,以评估这些变量。进行多变量分析以检查这些因素如何与非处方药过量个体的饮酒习惯相关。结果:非处方药过量在青少年和50多岁人群中普遍存在,并与习惯性酗酒和饮用能量饮料有关。那些过量服用非处方药的人大多是从药店和药房获得的。结论:这是第一个显示饮酒习惯与非处方药过量之间关系的研究。了解那些过量服用非处方药的人的饮酒习惯特征有助于减少这一人群的致命健康风险。
{"title":"Characteristics of the drinking habits of people who overdose over-the-counter drugs: Insights from a nationwide Japanese survey.","authors":"Satomi Mizuno, Satoshi Inoura, Toshihiko Matsumoto, Takuya Shimane","doi":"10.1002/pcn5.70027","DOIUrl":"10.1002/pcn5.70027","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the drinking habits of individuals who overdosed on over-the-counter (OTC) drugs, such as cough suppressants, antitussives, antipyretic analgesics, and combination cold medications, in Japan.</p><p><strong>Methods: </strong>This cross-sectional study analyzed data collected from 2881 participants through a national survey conducted in Japan in 2023. Through a self-administered questionnaire, the participants were categorized into OTC (overdosed OTC drugs in the past year) and control (did not overdose OTC drugs) groups. Variables related to drinking habits, social background, smoking habits, use of other medications, such as analgesics, tranquilizers, controlled drugs, and products containing high concentrations of caffeine, and perception of OTC drugs were compared between the two groups. Additionally, we matched the participants in the OTC (<i>n</i> = 25) and control (<i>n</i> = 100) groups by sex and age in a 1:4 ratio to assess these variables. Multivariate analyses were performed to examine how these factors are associated with drinking habits in individuals with OTC drug overdose.</p><p><strong>Results: </strong>OTC drug overdose was prevalent among teenagers and those in their 50s, and was associated with habitual binge drinking and consumption of energy drinks. Those overdosing on OTC drugs obtained them mostly from drugstores and pharmacies.</p><p><strong>Conclusion: </strong>This is the first study to show a relationship between drinking habits and OTC drug overdose. An understanding of the characteristics of drinking habits in those who overdose on OTC drugs can help reduce fatal health risks in this population.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70027"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11612021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A multicenter, single-group, open feasibility study of a new individual cognitive behavioral therapy program for adult Japanese patients with attention-deficit/hyperactivity disorder: Study protocol. 一项针对日本成年注意力缺陷/多动障碍患者的新的个体认知行为治疗方案的多中心、单组、开放式可行性研究:研究方案。
Pub Date : 2024-12-02 eCollection Date: 2024-12-01 DOI: 10.1002/pcn5.70036
Naoki Takamatsu, Misuzu Nakashima, Kei Matsuura, Ikue Umemoto, Masaya Ito, Junichiro Kanazawa, Hirofumi Tomiyama, Masaki Kondo, Hisateru Tachimori, Tomohiro Nakao, Masaru Horikoshi, Hironori Kuga

Background: Attention-deficit/hyperactivity disorder (ADHD) symptoms, including executive function, emotional regulation, and motivation, can persist into adulthood and are often associated with mental illnesses. Cognitive behavioral therapy (CBT) may help ADHD adults in Japan, but the lack of studies and the variability in group CBT approaches make its effects unclear. Japan lacks unified CBT programs and adult ADHD guidelines, making it difficult to implement international individual CBT recommendations due to cultural differences. This study will assess the feasibility of a novel CBT program for Japanese adult ADHD patients.

Methods: This feasibility study will be open, nonrandomized, single-arm, multicenter study. Twelve ADHD patients aged 20-65 years who are currently receiving treatment will be included based on Conners' Adult ADHD Rating Scale (CAARS) clinical severity threshold. An intervention phase of 12-16 weeks and a 12-week follow-up will total 24-28 weeks for all participants. The intervention will use a new CBT program tailored to individual assessments.

Results: The primary objective is to determine feasibility using dropout rates, adverse events, and CAARS score changes between Weeks 1 and 16. The secondary outcomes will assess long-term effects of treatment beyond the intervention period and provide descriptive statistics on sex, depression, quality of life, and autistic scores in relation to the intervention outcomes. The full analysis set and per protocol set will be used for statistical analysis.

Conclusions: This study is essential for the development of CBT interventions in accordance with Japan's healthcare system that are tailored to the unique needs of its population.

背景:注意缺陷/多动障碍(ADHD)症状,包括执行功能、情绪调节和动机,可以持续到成年,并且通常与精神疾病相关。认知行为疗法(CBT)可以帮助日本的多动症成年人,但缺乏研究和群体CBT方法的可变性使其效果不明确。日本缺乏统一的CBT计划和成人ADHD指南,由于文化差异,很难实施国际上的个体CBT建议。本研究将评估一种新的CBT方案对日本成人ADHD患者的可行性。方法:本可行性研究为开放、非随机、单组、多中心研究。根据Conners' Adult ADHD Rating Scale (CAARS)临床严重程度阈值,纳入12名目前正在接受治疗的20-65岁ADHD患者。所有参与者的干预期为12-16周,随访期为12周,共计24-28周。干预将使用一种针对个人评估量身定制的新的认知行为治疗方案。结果:主要目标是通过第1周至第16周的退学率、不良事件和CAARS评分变化来确定可行性。次要结果将评估干预期后治疗的长期效果,并提供与干预结果相关的性别、抑郁、生活质量和自闭症评分的描述性统计数据。完整的分析集和每个协议集将用于统计分析。结论:本研究对于开发符合日本医疗保健系统的CBT干预措施至关重要,该系统适合其人口的独特需求。
{"title":"A multicenter, single-group, open feasibility study of a new individual cognitive behavioral therapy program for adult Japanese patients with attention-deficit/hyperactivity disorder: Study protocol.","authors":"Naoki Takamatsu, Misuzu Nakashima, Kei Matsuura, Ikue Umemoto, Masaya Ito, Junichiro Kanazawa, Hirofumi Tomiyama, Masaki Kondo, Hisateru Tachimori, Tomohiro Nakao, Masaru Horikoshi, Hironori Kuga","doi":"10.1002/pcn5.70036","DOIUrl":"https://doi.org/10.1002/pcn5.70036","url":null,"abstract":"<p><strong>Background: </strong>Attention-deficit/hyperactivity disorder (ADHD) symptoms, including executive function, emotional regulation, and motivation, can persist into adulthood and are often associated with mental illnesses. Cognitive behavioral therapy (CBT) may help ADHD adults in Japan, but the lack of studies and the variability in group CBT approaches make its effects unclear. Japan lacks unified CBT programs and adult ADHD guidelines, making it difficult to implement international individual CBT recommendations due to cultural differences. This study will assess the feasibility of a novel CBT program for Japanese adult ADHD patients.</p><p><strong>Methods: </strong>This feasibility study will be open, nonrandomized, single-arm, multicenter study. Twelve ADHD patients aged 20-65 years who are currently receiving treatment will be included based on Conners' Adult ADHD Rating Scale (CAARS) clinical severity threshold. An intervention phase of 12-16 weeks and a 12-week follow-up will total 24-28 weeks for all participants. The intervention will use a new CBT program tailored to individual assessments.</p><p><strong>Results: </strong>The primary objective is to determine feasibility using dropout rates, adverse events, and CAARS score changes between Weeks 1 and 16. The secondary outcomes will assess long-term effects of treatment beyond the intervention period and provide descriptive statistics on sex, depression, quality of life, and autistic scores in relation to the intervention outcomes. The full analysis set and per protocol set will be used for statistical analysis.</p><p><strong>Conclusions: </strong>This study is essential for the development of CBT interventions in accordance with Japan's healthcare system that are tailored to the unique needs of its population.</p>","PeriodicalId":74405,"journal":{"name":"PCN reports : psychiatry and clinical neurosciences","volume":"3 4","pages":"e70036"},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11609744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142775352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PCN reports : psychiatry and clinical neurosciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1